Connect with us

Health Broadcasting Service

UK study suggests Delta subvariant less likely to cause symptoms

HBS Reporting

UK study suggests Delta subvariant less likely to cause symptoms

UK study suggests Delta subvariant less likely to cause symptoms

LONDON, Nov 18 (Reuters) – A subvariant of Delta that is growing in Britain is less likely to lead to symptomatic COVID-19 infection, a coronavirus prevalence survey found, adding that overall cases had dropped from a peak in October.

The Imperial College London REACT-1 study, released on Thursday, found that the subvariant, known as AY.4.2, had grown to be nearly 12% of samples sequenced, but only a third had “classic” COVID symptoms, compared with nearly a half of those with the currently dominant Delta lineage AY.4.

Two-thirds of people with AY.4.2 had “any” symptom, compared with more than three-quarters with AY.4.

AY.4.2 is thought to be slightly more transmissible, but it has not been shown to cause more severe disease or evade vaccines more easily than Delta.

The researchers said that asymptomatic people might self-isolate less, but also that people with fewer symptoms might spread it less easily through coughing and also may be unlikely to get severely ill.

“It is preferentially appearing to be more transmissible,” Imperial epidemiologist Paul Elliott told reporters. “It does seem to be less symptomatic, which is a good thing.”

Imperial had previously released interim results that showed COVID-19 prevalence was at its highest on record in October, with infections highest among children.

The full results of the latest round of the study, conducted between Oct. 19 and Nov. 5, confirmed what daily recorded cases and other prevalence surveys have shown – that infection levels dropped from that peak, corresponding with a half-term school holiday in late October.

Elliott said that there was uncertainty over whether that drop had continued, and the next few weeks would establish whether cases were rising again with the return of schools.

The REACT-1 study also found that booster doses reduced the risk of infection in adults by two-thirds compared with people who had two doses.

Continue Reading
You may also like...
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

More in HBS Reporting